We need your support to keep TheyWorkForYou running and make sure people across the UK can continue to hold their elected representatives to account.

Donate to our crowdfunder

Ocrelizumab

Department of Health and Social Care written question – answered on 5th December 2018.

Alert me about debates like this

Photo of Layla Moran Layla Moran Liberal Democrat Spokesperson (Education)

To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that (a) negotiations between Roche pharmaceuticals and NHS England on access to ocrelizumab for people with early primary progressive MS proceed immediately and (b) a new agreement is reached between those two parties.

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary for Health and Social Care

The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance on the use of ocrelizumab for the treatment of primary progressive multiple sclerosis. NHS England is in discussions with Roche, the manufacturer of ocrelizumab, to seek to agree a commercial agreement that might enable NICE to recommend use of the drug. Those discussions are rightly for NHS England and Roche and it would not be appropriate for Ministers to intervene.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.